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Abstract We describe a case of a post vaccine immune 
complex-mediated glomerulonephritis in an infant with 
compound heterozygous mutations of C2 complement 
component gene, which is the first such case in the litera-
ture. The three and a half months old boy presented with 
clinical and laboratory signs of nephritic syndrome and 
was successfully treated with methylprednisolone. An ex-
planation of such a clinical picture may lie in the interac-
tion between C2 deficiency and vaccination.
Nephritic syndrome may occur at any age, but is an un-
common finding in infants (1-6). It is caused by proliferative 
changes and inflammation in the glomeruli – proliferative 
glomerulonephritis (GN), which can be a primary/isolated 
disease or a consequence of a systemic disease. The most 
common types of primary proliferative GN in children are 
post-infectious GN, IgA nephropathy, and membranopro-
liferative GN, and the most common types of proliferative 
GN due to a systemic disease are Henoch Schönlein GN 
and lupus GN (1,5,6). All these conditions are immunologi-
cally mediated with in situ immune-complex formation or 
passive immune-complex trapping in the glomeruli and 
activation of secondary immune mechanisms like comple-
ment system.
We describe a case of presumably post-vaccine immune-
complex mediated GN in a three and a half months old 
boy in whom two heterozygous mutations on a C2 com-
plement component gene were found. The possible ad-
verse event after vaccination was reported to the National 
Institute of Public Health.
Case reporT
The patient was born to healthy, unrelated Caucasian par-
ents, at 39 weeks of gestation, weighing 4160 g. The preg-
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nancy was uneventful. His three and a half years old sister 
had a history of allergy to eggs and had been treated for 
many otitis media infections. The mother’s second preg-
nancy ended with spontaneous abortion in the first tri-
mester. The mother had a microhematuria of unknown 
cause. Patient’s parents gave a written informed consent 
for writing of this case report.
patient’s history and physical status
The boy was evaluated at the age of six weeks due to rash 
and suspected allergy to milk. The rash subsided when the 
mother, who was breastfeeding him, went on a milk-free 
diet. He was otherwise healthy until the day after his first 
vaccination against diphtheria, tetanus, pertussis, polio-
myelitis, Haemophilus influenza type B, and Pneumococ-
cus when he was three months old. The first vaccine was a 
combined one, containing active substances of Diphtheria 
toxoid, Tetanus toxoid, Bordetella pertussis antigens (Tox-
oid, Filamentoushaemagglutinin), type 1 poliomyelitisvirus 
(inactivated), type 2 poliomyelitisvirus (inactivated), type 3 
poliomyelitisvirus (inactivated), polysaccharide of Haemo-
philus influenzae type b conjugated to the tetanus protein 
and other ingredients including saccharose, trometamol, 
aluminum hydroxide, Hanks’ medium without phenol red, 
acetic acid, and/or sodium hydroxide for pH adjustment, 
formaldehyde, phenoxyethanol, and water for injections. 
The second vaccine was a Pneumococcal polysaccharide 
conjugate vaccine containing Pneumococcal polysaccha-
ride serotype 11,2, 41,2, 51,2, 6B1,2, 7F1,2, 9V1,2, 141,2, 18C1,3, 19F1,4, 
and 23F1,2 (1adsorbed on aluminum phosphate, 2conjugat-
ed to protein D, derived from non-typeable Haemophilus 
influenzae carrier protein, 3conjugated to tetanus toxoid 
carrier protein, 4conjugated to diphtheria toxoid carrier 
protein). Other excipients in the second vaccine were so-
dium chloride and water for injections.
The boy was febrile for three days starting from the day af-
ter vaccination, was well again for another fourteen days, 
and then suddenly presented with macrohematuria and 
mild periorbital edema. He was sent for evaluation to our 
department. The physician did not see him when was fe-
brile, so there were no firm data regarding the cause of the 
fever. Theoretically, this may have been the case of infec-
tion or nonspecific fever after vaccination.
At admission, he looked well although somewhat irritat-
ed, with no signs of respiratory tract infection, no skin 
rash, and with mild periorbital edema. He was very 
well grown, with weight of 7900 g (81st percentile) 
and height of 68 cm (95th percentile). The blood pressure 
was normal – 92/55 mm Hg, with pulse around 138/min. 
Physical exam of his heart, lung, abdomen, and extremities 
showed normal results. Peripheral pulses were palpable.
Course of treatment and medical examinations
We confirmed macrohematuria, accompanied also by 
nephrotic range proteinuria (maximum value of u-protein/
creatinine was 4104 g/mol), mild hypoproteinemia (mini-
mal value of serum proteins 47 g/L), hypoalbuminemia 
(minimal value of serum albumin 30 g/L), and elevated se-
rum concentration of urea (maximum 10.9 mmol/L) and 
creatinine (maximum 66 µmol/L – estimated glomerular 
filtration rate 41 mL/min/1.73 m2). Immunoglobulin lev-
els were as follows: IgE 13 kU/L (reference range from 0 
to 13 kU/L), IgG 5.72, IgA 0.52, and IgM 2.0 g/L (reference 
range for IgG 2.41 to 6.13, IgA 0.1 to 0.46, IgM 0.26 to 0.6 
g/L), while antistreptolysin 0 level was 54 IU/mL (reference 
range from 0 to 170 IU/mL). Blood pressure was normal 
all the time, but the boy needed furosemide to maintain 
diuresis. Kidneys were of normal shape and size but hy-
perechoic on ultrasound. At presentation, total hemolytic 
complement activity was very low (alternative pathway 40 
IU; reference range from 40 to 120 IU, classical pathway 9%; 
reference range from 72 to 128%). C3 component was only 
mildly decreased (851 mg/L; reference range from 970 to 
1576 mg/L), while concentrations of all other complement 
components were within the reference range, except for 
C2 component, which was extremely low (1.72 mg/L; ref-
erence range from 14 to 25 mg/L). C5-9 lytic complex was 
elevated in urine (424 µg/L; reference value less than 30 
µg/L) and in plasma it was within the reference range (303 
µg/L; reference range 300-350 µg/L). Anti-extractable nu-
clear antigen, antinuclear antibodies, anti-double stranded 
DNA antibodies, anticardiolipin antibodies, anti-beta2-gly-
coprotein I antibodies, antibodies against C1q, and anti-
neutrophil cytoplasmic antibodies were negative.
On the basis of clinical examination and the results of basic 
laboratory and morphologic tests, we reasonably suspect-
ed that the boy had nephritic syndrome, which was prob-
ably post-vaccine and that something was wrong with his 
complement system (very low C2).
Renal biopsy showed a diffuse, nonuniform endoprolifera-
tive (20/25 = 80%), mesangioproliferative (5/25 = 20%), and 
extracapillary crescentic (6/25 = 24%) GN. Extensive focal 
(40%-50%) active mixcellular tubulointerstitial nephritis 
was also found. Immunofluorescence analysis showed IgA 
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stained +/++ (on a scale from 0 to 4+), IgG +-, IgM +, kap-
pa and lambda +/++, C3 +/++, C1q +-, and fibrin/fibrino-
gen +-. Deposits, mostly IgA and C3, were located in the 
glomerular capillary wall and in the mesangium. Electron 
microscopy showed that deposits were mesangial and 
sub epithelial in cases when they did not form character-
istic humps. It was concluded that this was an immune 
complex-mediated GN, most probably an atypical post-
infectious GN (post-vaccine GN) with predominant IgA 
and C3 deposits in immune-complexes and no humps 
on electron microscopy. The composition of immune de-
posits described in our patient could also be found in IgA 
GN or Henoch-Schönlein Purpura, but the clinical course 
of our patient excluded these two conditions with great 
probability.
Due to unavailability of corresponding examinations, we 
could not prove specific antigens in glomerular immune 
complexes, but on the 25th day after vaccination it was 
confirmed that the boy had formed specific antibodies 
against some vaccines (IgG against Haemophilus influ-
enza type B was 0.5 mg/L, protective titer 1.0 mg/L; IgG 
against Pneumococcus 8.4 mg/L, protective titer 30.0 
mg/L; IgG against tetanus 0.27 IE/mL, protective titer 0.15 
IE/L; IgG against diphtheria 0.12 IE/L, protective titer 0.1 
IE/L). IgG against pertussis and poliomyelitis could not be 
tested in our laboratory. The boy was not re-vaccinated 
until the age of one.
The patient was treated with three pulses of methylpredni-
solone (10 mg/kg) for three consecutive days, followed by 
1 mg/kg of methylprednisolone daily for 6 weeks. There-
after, the steroids were tapered gradually and withdrawn 
completely in a 4-month period. He went into complete 
remission after 6 weeks of treatment and at the moment 
of writing of this report had been off all treatment for 4 
months and was doing fine. He had normal renal func-
tion, normal blood pressure, no proteinuria or hematuria, 
normal kidney ultrasound, but had persistently decreased 
total hemolytic complement activity (alternative pathway 
41 IU; reference range 40-120 IU, classical pathway 7%; ref-
erence range 72%-128%). C3 component and C5-9 lytic 
complex in urine normalized, while C2 component stayed 
low (3.16 mg/L; reference range 14-25 mg/L). The patient 
was found to be compound heterozygous for C2 gene. 
Two heterozygous mutations were found on his gene for 
C2 component. The first one was 28-base pair deletion of 
genomic DNA, which results in a premature termination 
of transcription. The second was a missense mutation that 
changes glutamate into aspartate at the position 298. The 
same mutations were found also in his older sister, while 
the parents refused to be tested.
DisCussion
This report presents a case of a three and a half months 
old patient who developed nephritic syndrome, which is 
an uncommon finding in infants. The patient had post-vac-
cine immune-complex mediated GN and two heterozy-
gous mutations on C2 complement component gene.
Genetically determined C2 deficiency is the most com-
mon of inherited complement deficiencies. Homozygous 
or complete C2 deficiency can present with a variety of 
symptoms – from asymptomatic state to systemic lupus 
erythematosus-like illness, polymyositis, glomerulonephri-
tis, Hodgkin lymphoma, vasculitis, Henoch-Schönlein pur-
pura, and recurrent pyogenic infections with encapsulated 
bacteria, such as Streptococcus pneumoniae, Haemophi-
lus influenza type b, and Neisseria meningitides. Patients 
may also have a combination of multiple autoimmune 
phenomena, especially various cutaneous manifestations 
and pyogenic infections (7-9). On the other hand, in most 
individuals partial C2 deficiency has no clinical importance 
(7,10,11).
Development of GN after vaccination has been reported 
earlier but as a very rare event and never in a patient with 
C2 deficiency. Post vaccine GN can present with a variety 
of clinical and histological pictures. It has been described 
after hyperimmunization with pertussis vaccine as a diffuse 
vasculitis and death (12), after influenza H1N1 vaccination 
as a membranous GN (13), after hepatitis B vaccine as a 
vaccine-related systemic lupus erythematosus (14), and af-
ter pneumococcal vaccination as a crescentic GN due to 
anti glomerular basement membrane disease (15). Neph-
rotic syndrome has been described after measles vaccina-
tion (16) and after anti rabies vaccine (17).
Our patient was simultaneously vaccinated against diph-
theria, tetanus, pertussis, polio, Haemophilus influenza 
type B, and Pneumococcus. Eighteen days after vaccina-
tion he presented with clinical and laboratory signs of ne-
phritic syndrome. Immune complex-mediated GN was 
histologically confirmed with predominant IgA and C3 
deposits in immune complexes and no humps on elec-
tron microscopy. Specific antigens in glomerular immune 
complexes could not have been proven, but it was prov-
en that the boy had formed specific antibodies in pro-
tective titers against all the received vaccines. There-
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fore, the predisposition for his atypical post-infectious or 
post-vaccine GN theoretically could have been any com-
pound of any vaccine, as well as an infection he could have 
had before the onset of nephritic syndrome. In addition, 
two heterozygous mutations on C2 complement compo-
nent gene were found, both already described (18,19), but 
not in compound heterozygous patients, which could ex-
plain the extreme C2 deficiency in our patient.
There was a question about patient’s further vaccination. 
Since approximately 50% of C2-deficient patients have an 
increased susceptibility to blood borne infections caused 
with encapsulated organisms (eg, pneumococcus, H. influ-
enza, and meningococcus), vaccination represents a treat-
ment of choice against sepsis, meningitis, arthritis, and os-
teomyelitis (7-9). On the other hand, they are at increased 
risk of developing systemic lupus erythematosus, glom-
erulonephritis, inflammatory bowel disease, dermatomyo-
sitis, anaphylactoid purpura, and vasculitis (7-9), all these 
conditions being possibly triggered by environmental fac-
tors like infection or vaccination. The boy’s parents were 
very anxious about further vaccination, so it was decided 
against it and the child was put on antibiotic prophylaxis 
with penicillin until a different decision is made.
In conclusion, this is the first case report that describes 
post vaccine immune complex-mediated GN in an infant 
with compound heterozygous mutations on C2 comple-
ment component gene. An explanation of such a clinical 
picture may lie in the interaction between C2 deficiency 
and vaccination.
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